(NASDAQ: AUTL) Autolus Therapeutics's forecast annual revenue growth rate of 59.73% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.67%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.07%.
Autolus Therapeutics's revenue in 2026 is $75,388,000.On average, 14 Wall Street analysts forecast AUTL's revenue for 2026 to be $35,631,263,130, with the lowest AUTL revenue forecast at $30,984,401,356, and the highest AUTL revenue forecast at $41,079,216,194. On average, 14 Wall Street analysts forecast AUTL's revenue for 2027 to be $54,599,295,123, with the lowest AUTL revenue forecast at $37,531,526,192, and the highest AUTL revenue forecast at $72,726,314,332.
In 2028, AUTL is forecast to generate $83,851,103,687 in revenue, with the lowest revenue forecast at $52,448,857,372 and the highest revenue forecast at $123,125,868,402.